GSK vs Pfizer
GSK and PFE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GSK and PFE compare
GSK grew revenue faster over the last twelve months (4.1% versus −0.21% for Pfizer).
GSK keeps more of each dollar of sales as profit, with a net margin of 17.5% compared with 6.8% at Pfizer.
Pfizer pays a dividend yielding 5.7%; GSK does not pay one.
Pfizer scores higher on the StockData Score (11 against 9 for GSK), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GSK | PFE |
|---|---|---|
| Size and price | ||
| Market cap | – | $171B |
| Share price | $49.51 | $29.95 |
| Change, 1 year | 7.8% | 22.2% |
| Change, 5 years | −7.1% | −38.4% |
| Beta (5Y) | 0.26 | 0.44 |
| Employees | 500K | 75K |
| StockData Score | ||
| Total score | 9 | 11 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 | 2 |
| Performance score | 4 (better) | 2 |
| Health score | 3 (better) | 2 |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | – | 39.4× |
| P/S | – | 2.7× |
| P/B | – | 2.0× |
| EV/EBITDA | – | 16.7× |
| P/FCF | – | 15.5× |
| FCF yield | – | 6.4% |
| Fair value | – | $19.52 |
| Margin of safety | – | −53.4% |
| Growth | ||
| Revenue growth (TTM) | 4.1% (better) | −0.21% |
| Revenue growth, 5Y average | 6.0% | 8.5% (better) |
| Net income growth (TTM) | 122% (better) | −59.7% |
| EPS growth (TTM) | 123% (better) | −59.6% |
| EPS growth, 5Y average | −0.54% (better) | −3.6% |
| Profitability | ||
| Gross margin | 72.4% | 73.2% (better) |
| Operating margin | 24.3% | – |
| Net margin | 17.5% (better) | 6.8% |
| FCF margin | 19.6% (better) | 17.2% |
| Return on equity | 38.0% (better) | 5.0% |
| Return on invested capital | 23.4% | – |
| Financial health | ||
| Debt / equity | 1.08 | 0.74 (better) |
| Net debt / EBITDA | 1.40 (better) | 4.07 |
| Interest coverage | 11.3× | – |
| Current ratio | 0.82 | 1.27 (better) |
| Altman Z-score | – | 2.03 |
| Piotroski F-score | 9 (better) | 6 |
| Dividends and buybacks | ||
| Dividend yield | – | 5.7% |
| Payout ratio | 44.9% | – |
| Years of dividend growth | – | 15 |
| Dividend growth, 5Y average | – | 2.4% |
| Shareholder yield | – | 5.7% |
| Ownership | ||
| Held by institutions | 8.0% | 67.2% |
| Held by insiders | 0.05% | 0.03% |
| Insider net buying, 12 months | – | $2.8M |
| Superinvestors holding | 1 | 2 (better) |
| Short interest, % of float | – | 2.6% |
Go deeper
- GSK stock overview
- GSK income statement
- GSK valuation and score
- PFE stock overview
- PFE income statement
- PFE valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.